Furthermore, preliminary results of BCMA/CD19 targeted CARs in the treatment of multiple myeloma suggest BCMA/CD19 targeted CARs are highly efficacious with favorable safety profiles48,49. Here, CD19 is linked to plasma cell myeloma.